ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

DCE Board Approves Concepts For New Chemoprevention Groups, Retroviral Vaccine Research, Biochemical Markers, Feline Virus Studies

March 15, 1985

Trials Approved by NCI CTEP For the Month of May

May 25, 2012

ACCC Joins ONS In Opposing RCT Caregiver Category

March 31, 1989

NCI TO Issue RFA For Gene Therapy Studies; $20 Mil. Se-Aside Ok’d

January 10, 1992

Conversation with The Cancer Letter: Kazerooni: The Case for Broad Coverage

March 21, 2014

NAS To Honor Outstanding Scientists

February 28, 1997